Schouw & Co. share buy-back programme, week 46 2022
On 27 December 2021, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 10 of 21 December 2021. Under the programme, Schouw & Co. will acquire shares for up to DKK 350 million during the period 27 December 2021 to 30 December 2022.
The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).
| Trading day | No. of shares | Average price | Amount | ||
| Accumulated until 11/11/2022 | 490,823 | 531.66 | 260,949,047 | ||
| Monday, 14 November 2022 | 1,348 | 487.83 | 657,595 | ||
| Tuesday, 15 November 2022 | 0 | - | - | ||
| Wednesday, 16 November 2022 | 0 | - | - | ||
| Thursday, 17 November 2022 | 0 | - | - | ||
| Friday, 18 November 2022 | 0 | - | - | ||
| In the period 14/11/2022 - 18/11/2022 | 1,348 | 487.83 | 657,595 | ||
| Accumulated 27/12/2021 - 18/11/2022 | 492,171 | 531.54 | 261,606,642 | ||
| Following the above transactions, Schouw & Co. holds a total of 2,012,895 treasury shares corresponding to 7.89% of the total share capital of 25,500,000 shares. | |||||
Aktieselskabet Schouw & Co.
Jørgen Wisborg, Chairman
Jens Bjerg Sørensen, President, +45 8611 2222
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release
As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as
Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Investeringsforeningen IA Invest, Afdeling Furesø Globale Kvalitetsaktier – Endeligt resultat af tegning6.5.2024 14:20:15 CEST | pressemeddelelse
Investeringsforeningen IA Invest havde indledende tegningsperiode i følgende afdeling fra den 22. april til og med den 3. maj 2024. Endeligt resultat af tegningen fremgår nedenfor: AfdelingISINTegningskursAntal investorerAntal cirkulerende andeleFormue kr.Furesø Globale KvalitetsaktierDK0062842217100,2033425.234 42.608.447 De nye andele vil blive optaget til handel på Nasdaq Copenhagen med første handelsdag den 14. maj 2024. For yderligere information henvises der til henholdsvis foreningens og afdelingens hjemmeside www.iainvest.dk og www.furesoekapital.dk. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør
Exodus Movement, Inc. Announces Uplist to NYSE American Exchange6.5.2024 14:15:00 CEST | Press release
OMAHA, Neb., May 06, 2024 (GLOBE NEWSWIRE) -- Exodus Movement, Inc. (OTCQX: EXOD) (“Exodus” or the “Company”), the leading self-custodial cryptocurrency software platform, today announced that its common stock has been approved for listing on the NYSE American stock exchange. The Company’s Class A common stock, par value $0.000001 (the “Common Stock”), will begin trading on the NYSE American under its current symbol, “EXOD,” at the open of trading on May 9, 2024. The Common Stock will continue to trade on the OTCQX until the close of market on May 8, 2024. Current stockholders of the Company do not need to take any action prior to the Company’s expected listing on the NYSE American. “Uplisting to the NYSE American marks a significant milestone in our journey. Trading on the NYSE American will allow Exodus to create greater long-term value for our stockholders by increasing our presence within the investor community and, in turn, increase liquidity,” said JP Richardson, CEO and co-found